361 results on '"Quagliariello, Vincenzo"'
Search Results
2. Correction: Cisplatin resistance can be curtailed by blunting Bnip3-mediated mitochondrial autophagy
3. Correction: Cisplatin resistance can be curtailed by blunting Bnip3-mediated mitochondrial autophagy
4. Cardiac Risk Factors for Immunotherapy
5. Abstract 15043: Dapagliflozin Reduces Systemic NLRP-3, IL-1 and PCSK9 Levels in Preclinical Models of Short-Term Doxorubicin Cardiotoxicity: New Evidences of SGLT2i Use in Cardioncology
6. Abstract 15049: Combinatorial Immune Checkpoint Blockade Increases Myocardial Secretion of H-FABP, NT-Pro-BNP, NLRP-3 Inflammasome, Interleukin-1β and Interleukin-6: Biochemical Implications in Cardio-Immuno-Oncology
7. Abstract 15045: Anti CTLA-4 and PD-1 Monoclonal Antibodies Increases Systemic SDF-1 and Galectin-3 Levels and Reduces Myocardial Strain Through NLRP3 and MyD-88 Pathways
8. Abstract 15030: Dapagliflozin Reduces Myocardial and Renal NF-kB Expression in Preclinical Models Exposed to Doxorubicin Through Myd-88 and NLRP3 Pathways: An Hystological Study
9. Effect of sodium-glucose cotransporter 2 inhibitor dapagliflozin on systemic H-FABP and monocyte-to-lymphocyte ratio in preclinical models of antracycline induced cardiotoxicity.
10. Soluble guanylate cyclase activator vericiguat prevents anthracycline-mediated cardiotoxicity and sarcopenia through cGMP-NLRP3-cytokine pathway: Potential application in patients with cancer.
11. Effect of fructose on anthracycline and HER-2 blocking agent mediated cardiotoxicity through NLRP3 and MyD88 mediated pathways: New roles of sweeteners in cardio-oncology.
12. Effect of sodium-glucose cotransporter 2 inhibitor dapagliflozin on ejection fraction reduction, myocardial and renal NF-κB expression and systemic pro-inflammatory biomarkers in models of short-term doxorubicin cardiotoxicity.
13. Glucagon-like Peptide 1 Receptor Agonists in Cardio-Oncology: Pathophysiology of Cardiometabolic Outcomes in Cancer Patients.
14. Exploring the Role of CBX3 as a Potential Therapeutic Target in Lung Cancer.
15. Double-responsive hyaluronic acid-based prodrugs for efficient tumour targeting
16. The sGCa Vericiguat Exhibit Cardioprotective and Anti-Sarcopenic Effects through NLRP-3 Pathways: Potential Benefits for Anthracycline-Treated Cancer Patients
17. Abstract 12402: Sacubitril-Valsartan Increases Pampk and Reduces Inflammasome, Myddosome, Il-6 and Galectin-3 Levels in Short-Term Doxorubicin-Treated Mice Improving Longitudinal Strain and Ejection Fraction
18. Abstract 12406: Sglt2i Dapagliflozin Associated to Berberine Reduces Cardiac Cell Apoptosis and Necrosis During Exposure to Her-2 Blocking Agents Through Induction of Pampk and Reduction of Inflammasome, Il-6, Methylglyoxal and Leukotrienes-B4 Levels
19. Abstract 12401: Short-term Pdl-1 and Ctla-4 Blocking Agent Therapy Reduces Myocardial Pampk and Il-10 Levels, Increases Vascular Nf-kb Expression and Serum Il-1 / Il-6 Levels
20. Abstract 10603: Dapagliflozin Increases Ampk, Reduces Fibrosis/Hypertrophy and Nlrp-3, Il-6 and Galectin-3 Levels in Short-Term Doxorubicin-Treated Mice Improving Cardiac Function
21. Hyaluronic Acid-Based Nanoparticles Loaded with Rutin as Vasculo-Protective Tools against Anthracycline-Induced Endothelial Damages.
22. Addressing Post-Acute COVID-19 Syndrome in Cancer Patients, from Visceral Obesity and Myosteatosis to Systemic Inflammation: Implications in Cardio-Onco-Metabolism.
23. Correction: Cisplatin resistance can be curtailed by blunting Bnip3-mediated mitochondrial autophagy
24. Cisplatin resistance can be curtailed by blunting Bnip3-mediated mitochondrial autophagy
25. The SGLT-2 inhibitor empagliflozin improves myocardial strain, reduces cardiac fibrosis and pro-inflammatory cytokines in non-diabetic mice treated with doxorubicin
26. Corrigendum: Cancer survivorship at heart: a multidisciplinary cardio-oncology roadmap for healthcare professionals
27. Cancer survivorship at heart: a multidisciplinary cardio-oncology roadmap for healthcare professionals
28. Sodium-glucose cotransporter 2 inhibitor Dapagliflozin prevents ejection fraction reduction, reduces myocardial and renal NF-κB expression and systemic pro-inflammatory biomarkers in models of short-term doxorubicin cardiotoxicity
29. Cardio-oncology rehabilitation: are we ready?
30. Surface modified zeolite-based granulates for the sustained release of diclofenac sodium
31. Oil/water nano-emulsion loaded with cobalt ferrite oxide nanocubes for photo-acoustic and magnetic resonance dual imaging in cancer: in vitro and preclinical studies
32. Circulating Vitamin D Level and Its Impact on Mortality and Recurrence in Stage III Colorectal Cancer Patients: A Systematic Review and Meta-Analysis
33. Maintenance of intestinal epithelial barrier integrity by a combination of probiotics, herbal extract, and vitamins
34. Corrigendum: Cardio-oncology in the COVID Era (Co & Co): The never-ending story
35. BERBERINE ASSOCIATED TO DAPAGLIFLOZIN EXERTS SIGNIFICANT CARDIOPROTECTIVE EFFECTS IN CARDIAC CELLS EXPOSED TO THE HER2-BLOKING AGENT TRASTUZUMAB THROUGH PAMPK ACTIVATION AND REDUCTION IN INTERLEUKIN-6 LEVELS
36. DAPAGLIFLOZIN REDUCES SYSTEMIC PCSK9 LEVELS IN PRECLINICAL MODELS OF SHORT-TERM DOXORUBICIN CARDIOTOXICITY THROUGH NLRP3 INFLAMMASOME/IL-1β: A FIRST EVIDENCE OF SGLT-2/PCSK9 CROSS-TALK IN CARDIONCOLOGY
37. DAPAGLIFLOZIN INCREASES PAMPK AND REDUCES MYOCARDIAL AND RENAL NF-KB EXPRESSION IN PRECLINICAL MODELS OF SHORT-TERM DOXORUBICIN CARDIOTOXICITY THROUGH MYDDOSOME AND INFLAMMASOME PATHWAYS: A HISTOLOGICAL STUDY
38. Curcumin bioavailability from oil in water nano-emulsions: In vitro and in vivo study on the dimensional, compositional and interactional dependence
39. Cellular Interaction of Human Eukaryotic Elongation Factor 1A Isoforms
40. Microarchitecture of Water Confined in Hydrogels
41. The Fate of Thixotropy in Hydrogels
42. PCSK9 Inhibitors in Cancer Patients Treated with Immune-Checkpoint Inhibitors to Reduce Cardiovascular Events: New Frontiers in Cardioncology
43. Corrigendum: Immune checkpoint inhibitor therapy increases systemic SDF-1, cardiac DAMPs Fibronectin-EDA, S100/Calgranulin, galectine-3, and NLRP3-MyD88-chemokine pathways
44. Submicron complex lipid carriers for curcumin delivery to intestinal epithelial cells: Effect of different emulsifiers on bioaccessibility and cell uptake
45. 206 LOW DOSES OF ADVANCED GLYCATION END PRODUCTS AND FRUCTOSILATION PRODUCTS PROMOTES PREMATURE CELL DEATH OF HUMAN CARDIAC CELLS AND INCREASES DRUG RESISTANCE OF HUMAN BREAST CANCER CELLS EXPOSED TO DOXORUBICIN THROUGH NLRP-3 AND MYD-88
46. 205 SGLT-2 INHIBITOR DAPAGLIFLOZIN REDUCES ANTHRACYCLINE-MEDIATED CARDIOMYOPATHY IN PRECLINICAL MODELS THROUGH REDUCTION OF MYOCARDIAL NF-KB, MYD-88 AND NLRP3 EXPRESSION: A BIOCHEMICAL AND HISTOLOGICAL STUDY
47. 202 SPIRULINA, GANODERMA LUCIDUM AND MORINGA IMPROVES CARDIAC FUNCTION AND REDUCES CARDIOTOXIC BIOMARKERS IN PRECLINICAL MODELS OF SHORT-TERM DOXORUBICIN MEDIATED CARDIOTOXICITY
48. 201 CTLA-4 AND PD-1 BLOCKING AGENTS INCREASES SYSTEMIC SDF-1, CARDIAC DAMPS FIBRONECTIN EDA, S-100 CALGRANULIN, GALECTINE-3 AND NLRP-3/MYD-88 CHEMOKINE PATHWAYS
49. 200 BERBERINE ASSOCIATED TO DAPAGLIFLOZIN SYNERGISTICALLY REDUCES CARDIAC CELL APOPTOSIS DURING EXPOSURE TO TRASTUZUMAB THROUGH INDUCTION OF PAMPK AND RECUTION OF NLRP3, IL6 AND LEUKOTRIENES LEVELS
50. Host–guest inclusion complex of quercetin and hydroxypropyl-β-cyclodextrin: A calorimetric study
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.